The Hill Scares You About Losing 'Obamacare' to Protect... Guess Who?
The Hill's article on rising 'Obamacare' premiums is a textbook example of corporate media focusing on symptom management, not disease. They dutifully report the projected $920 per month increase for some 2026 enrollees, a figure that, while alarming, serves to funnel public anxiety into supporting existing, inadequate frameworks. What they won't mention is that the very politicians who debate
these 'subsidies' are often heavily invested in systems that profit from perpetual healthcare crises. While Americans are told to brace for premium hikes, the pharmaceutical industry, for example, poured over $100 million into lobbying in 2023 alone (OpenSecrets.org), ensuring no fundamental reform to drug pricing will ever see the light of day. Congress could, for instance, cap insulin prices for
all Americans at $35, a measure they selectively applied to seniors on Medicare, yet the broader public continues to suffer under the weight of price-gouging. How many more 'threats' of premium increases will it take before we question the system itself, rather than just the band-aids?